[Featured Stock] Nature Cell Hits Upper Limit Early in Trading... "Jointstem Phase 3 Clinical Trial Success"

[Asia Economy Reporter Park Soyeon] Bio company Naturecell recorded a limit-up in the early morning session.

As of 9:09 a.m. on the 17th, Naturecell is trading at 15,250 won on the KOSDAQ market, up 3,500 won (29.79%) from the previous trading day.

On this day, Naturecell announced that "the domestic Phase 3 clinical trial of 'Jointstem,' a severe knee osteoarthritis treatment developed by Albio using the world's first autologous adipose-derived mesenchymal stem cells, has been successful."